---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-024877"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:05:23.721536+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics appoints Scott Myers as President and CEO, succeeding Jonathan Violin

## Summary
- Scott Myers, former CEO of AMAG Pharmaceuticals, appointed President & CEO and Class III Director effective Feb 6, 2023.
- Founding CEO Jonathan Violin steps down; receives 18-month salary severance, 12-month accelerated option vesting, and consulting role.
- Myers granted inducement award of 1,000,000 stock options and 250,000 RSUs, vesting over 4 years with first cliff at 12 months.
- Company references positive topline data from Phase 1/2 trial of VRDN-001 for thyroid eye disease (previously filed presentation).

## SEC filing metadata
- accession: 0001193125-23-024877
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/d406212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-024877
- JSON: https://secwatch.observer/filing/0001193125-23-024877.json
- Plain text: https://secwatch.observer/filing/0001193125-23-024877.txt

## Key facts
- Executive change
  Scott Myers was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointment of Scott Myers as the Company’s President and Chief Executive Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm
- Executive change
  Scott Myers was appointed as Class III Director at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Class III Director
  source text: Mr. Myers was also appointed as a Class III Director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.